Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-P6 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Celltrion
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**CT-P6 + paclitaxel** is a combination therapy consisting of CT-P6, a biosimilar of trastuzumab (a monoclonal antibody targeting HER2), together with paclitaxel (a microtubule inhibitor), used primarily for the treatment of **HER2-positive breast cancer**. CT-P6 binds to the HER2 receptor, inhibiting downstream signaling pathways (AKT and ERK1/2), reducing cell proliferation, and inducing antibody-dependent cellular cytotoxicity (ADCC). Paclitaxel stabilizes microtubules, preventing mitosis and cell division. The combination exhibits equivalent efficacy and safety to reference trastuzumab (Herceptin) plus paclitaxel and is frequently used in neoadjuvant and metastatic settings. CT-P6 was developed to provide a cost-effective alternative to reference trastuzumab, showing similar clinical outcomes when combined with taxanes such as paclitaxel[1][2].
- Brand names
- Herzuma
- Other names
- trastuzumab biosimilar + paclitaxel
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on CT-P6 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-P6 + paclitaxel.